Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance

References

• International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels (Belgium): IDF; 2015 [cited 2016 Mar 17]. Available from http://www.idf.org/diabetesatlas
   Google Scholar
• Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag. 2009;12:103–110.
   PubMed Web of Science ®Google Scholar
• Owens DR, Bolli GB. Beyond the era of NPH insulin–long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008;10:333–349.
   PubMed Web of Science ®Google Scholar
• Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30:104–119.
   PubMed Web of Science ®Google Scholar
• Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2015 Oct 28. [Epub ahead of print]. doi:10.1002/dmrr.2763.
   PubMed Web of Science ®Google Scholar
• Eli Lilly. Lilly ends basal insulin Peglispro development program. Press release; 2015 Dec 4 [cited 2016 Apr 17]. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=945541
   Google Scholar
• Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787–800.
   PubMed Web of Science ®Google Scholar
• Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13:677–684.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443–445.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for medicinal products for human use (CHMP) assessment report for Toujeo (insulin glargine); 2015 Feb 26 [cited 2016 Mar 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000309/WC500186579.pdf
   Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–2762.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–3243.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386–394.
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38:2217–2225.
   PubMed Web of Science ®Google Scholar
• Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016;18:375–383.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016;18:366–374.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17:254–260.
   PubMed Web of Science ®Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units.mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units.mL−1. Diabetes Care. 2015;38:637–643.
   PubMed Web of Science ®Google Scholar
• Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17:261–267.
   PubMed Web of Science ®Google Scholar
• Jinnouchi H, Koyama M, Amano A, et al. Continuous glucose monitoring during basal-bolus therapy using insulin glargine 300 U mL−1 and glargine 100 U mL−1 in Japanese people with type 1 diabetes mellitus: a crossover pilot study. Diabetes Ther. 2015;6:143–152.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Bailey TS, Rodbard D, et al. Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with type 1 diabetes mellitus measured with continuous glucose monitoring (CGM) (abstract 949). Diabetologia. 2014;57:S388–S389.
   Google Scholar
• Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148.
   PubMed Web of Science ®Google Scholar
• Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644–649.
   PubMed Web of Science ®Google Scholar
• Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23:813–819.
   PubMed Web of Science ®Google Scholar
• Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240–1244.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–867.
   PubMed Web of Science ®Google Scholar
• Jorgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50:161–167.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Toujeo (insulin glargine U300): summary of product characteristics, version 8 July 2015; [cited 2016 Mar 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf.
   Google Scholar
• Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014;16:873–876.
   PubMed Web of Science ®Google Scholar
• Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin. 2003;19:34–40.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35:2626–2630.
   PubMed Web of Science ®Google Scholar
• Lucidi P, Porcellati F, Rossetti P, et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care. 2012;35:2647–2649.
   PubMed Web of Science ®Google Scholar
• Sommerfeld MR, Muller G, Tschank G, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One. 2010;5:e9540.
   PubMed Web of Science ®Google Scholar
• Arnolds S, Kuglin B, Kapitza C, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64:1415–1424.
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648–659.
   PubMed Web of Science ®Google Scholar
• sanofi-aventis U.S.LLC. Toujeo (insulin glargine injection) U-300, for subcutaneous use. Prescribing information; 2015 Sep [cited 2016 Mar 17]. Available from: http://products.sanofi.us/toujeo/toujeo.pdf.
   Google Scholar
• Sanofi. Comparison of the safety and efficacy of HOE901-U300 with Lantus in children and adolescents with type 1 diabetes mellitus (EDITION JUNIOR); [cited 2016 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02735044.
   Google Scholar
• Twigg SM, Escalada J, Grisoni M-L, et al. Age, BMI, and diabetes duration: effect on glycemic control and hypoglycemia with insulin glargine 300 U/mL in type 2 diabetes (T2DM) (abstract 1017P). Diabetes. 2015;64:A260.
   Google Scholar
• Sanofi. Comparison of the safety and efficacy of HOE901-U300 with lantus in older patients with type2 diabetes insufficiently controlled on their current Antidiabetic Medications (SENIOR); [cited 2016 May 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02320721.
   Google Scholar
• Riddle MC, Yki-Jarvinen H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17:835–842.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015;17:1142–1149.
   PubMed Web of Science ®Google Scholar
• Matsuhisa M, Koyama M, Cheng X, et al. Sustained glycemic control and less nocturnal hypoglycemia with new insulin glargine 300 U/mL compared with glargine 100 U/mL over 12 months in Japanese people with T1DM (EDITION JP 1). Diabetes. 2015;64:A250.
   Google Scholar
• Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/mL provides sustained glycemic control and reduced hypoglycemia over 12 months compared with glargine 100 U/mL in Japanese people with T2DM managed with basal insulin plus OAD(s) (EDITION JP 2). Diabetes. 2015;64:A26.
   Google Scholar
• Sanofi. Clinical study report; 2015 May 20. 6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus® in insulin naïve patients with type 2 diabetes mellitus not adequately controlled with non-insulin antihyperglycemic drugs with a 6-month safety extension period (EFC12347[12 months]); [cited 2016 May 20]. Available from: http://en.sanofi.com/img/content/study/efc12347_summary.pdf.
   Google Scholar
• Sanofi. Clinical study report. 2015 May 20. A 6-month, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of a new formulation of insulin glargine and Lantus® injected in the morning or evening in patients with type 1 diabetes mellitus with a 6-month safety extension period (EFC12456 12 months); [cited 2016 May 20]. Available from: http://en.sanofi.com/img/content/study/efc12456_summary.pdf.
   Google Scholar
• Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18:252–257.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245–1249.
   PubMed Web of Science ®Google Scholar
• Goldman J, White JR Jr. New insulin glargine 300 U/mL for the treatment of type 1 and type 2 diabetes mellitus. Ann Pharmacother. 2015;49:1153–1161.
   PubMed Web of Science ®Google Scholar
• Dailey G, Lavernia F. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Diabetes Obes Metab. 2015;17:1107–1114.
   PubMed Web of Science ®Google Scholar
• Blair HA, Keating GM. Insulin glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76:363–374.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open. 2016;6:e009421.
   PubMed Web of Science ®Google Scholar